A breakthrough breast cancer vaccine has completed Phase one trials, with over 75 percent of participants showing a strong immune response, raising hopes it could help eradicate the disease by 2030.
The vaccine, developed by Anixa Biosciences and the Cleveland Clinic, targets alpha‑lactalbumin, a milk protein linked to aggressive triple-negative breast cancer, to help prevent and treat the disease. That form of cancer is known as the most deadly.
